Cord Blood News 10.44 November 8, 2018 | |
| |
TOP STORYThe authors showed that the intravitreal transplant of Wharton´s jelly MSCs isolated from three different human umbilical cords delays axotomy-induced retinal ganglion cell loss. [Sci Rep] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists designed a reliable 3D differentiation process of human Wharton’s jelly MSCs into pancreatic beta cell precursors (PBCPs) and detected that transplanted PBCPs could improve hyperglycemia in a diabetes‐induced model in mice. [J Cell Physiol] Abstract Effects of HLA Mismatch on Cytomegalovirus Reactivation in Cord Blood Transplantation Researchers focused on cord blood transplantation and examined the effects of human leukocyte antigen (HLA) mismatch on the incidence of cytomegalovirus reactivation while minimizing the effects of acute graft-versus-host disease. [Bone Marrow Transplant] Abstract While 50% of hyperbaric oxygen (HBO)-treated patients received single umbilical cord blood (UCB) units, ~90% of the control patients received double UCB units. Although HBO patients had much better rates of survival at 6 months, their 1-year survival did not significantly differ from the control group. HBO-treated patients had on average lower relapse and non-relapse mortality rates, and less chronic graft versus host disease (GvHD), but had increased acute GvHD. [Ann Hematol] Abstract Allogeneic rat PKH26-labeled umbilical cord-derived MSCs were administered by direct intramuscular injection. Animals of experimental group responded to the transplantation by improvement in their locomotor function as assessed by the rotarod performance test on day 9 and 29 after transplantation. [Histol Histopathol] Abstract MSCs were successfully obtained from vitrified Wharton’s Jelly (WJ) tissues retaining their morphological and multilineage differentiation properties. Furthermore, MSCs from vitrified WJ tissues successfully expressed HLA-G. [Bioengineering (Basel)] Abstract Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News. | |
| |
REVIEWSCurrently, the use of umbilical cord blood (UCB)-based interventions for cerebral palsy is limited as the components of UCB are complex and possess different therapeutic mechanisms. These can be categorized by three aspects: homing and neuroregeneration, trophic factor secretion, and neuroprotective effects. The authors summarize the features of active components of UCB and their therapeutic mechanism of action. [Cell Transplant] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
SCIENCE NEWSExCellThera Announces Clinical Trial Results Using ECT-001 to Be Presented ExCellThera Inc. announced that results from the Phase I/II clinical trial using its lead technology, ECT-001, for allogeneic stem cell transplant, will be presented. [Press release from ExCellThera Inc. discussing research to be presented at the 2018 American Society of Hematology (ASH) Annual Meeting, San Diego] Press Release Magenta Therapeutics announced that the company will present clinical data and preclinical research. [Press release from Magenta Therapeutics discussing research to be presented at the 2018 American Society of Hematology (ASH) Annual Meeting, San Diego] Press Release | |
| |
INDUSTRY NEWSCity of Hope, TGen Announce Letter of Intent to Build Cell Therapy Manufacturing Facility in Phoenix City of Hope and its affiliate, Translational Genomics Research Institute (TGen), have announced a letter of intent to develop a state-of-the-art cell therapy manufacturing facility in the Phoenix Metropolitan Area, a move that would improve the speed at which stem cell research and cancer treatment is delivered. [TGen] Press Release Daiichi Sankyo Company, Limited announced that the European Medicines Agency (EMA) validated for review and granted accelerated assessment to the Marketing Authorization Application for quizartinib for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) which is FLT3-ITD positive. [Daiichi Sankyo Company, Limited] Press Release GT Biopharma, Inc. announced that its Investigational New Drug application to the FDA is now open and it is authorized to initiate a first-in-human Phase I study with GTB-3550 for the treatment of acute myelogenous leukemia, myelodysplatic syndrome and mastocytosis. [GT Biopharma, Inc.] Press Release Modus Therapeutics Announces FDA Acceptance of Sevuparin IND for Treatment of Sickle Cell Disease Modus Therapeutics AB announced that the FDA has accepted its sevuparin IND for the treatment of sickle cell disease. [Modus Therapeutics AB] Press Release | |
| |
POLICY NEWSScientists Struggle with Confusing Journal Guidelines Globally, more than two-thirds of researchers find it difficult to prepare manuscripts and to respond to peer-review comments, finds a survey of nearly 7,000 researchers from over 100 countries. [Nature News] Editorial Open-Access Plan Draws Online Protest Hundreds of scientists are pushing back against Plan S, a plan to crack down on scholarly journals’ paywalls, launched 2 months ago by 11 national research funders in Europe. In an open letter published on 5 November, about 800 signatories say they support open access—making papers available free to all readers online—but condemn Plan S as “too risky for science”. [ScienceInsider] Editorial Europe’s Researchers Benefit From Reduced Bureaucracy The European Union has made good on its promise to reduce the amount of red tape that scientists must wade through when applying for grants from its flagship funding program, according to a report released by the European Court of Auditors. [Nature News] Editorial
| |
EVENTSNEW Keystone Symposia: Genome Engineering: From Mechanisms to Therapies Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Research Scientist – Hematopoietic Stem Cells (Columbia University Medical Center) Faculty Position – GvHD or Immunotherapy (Medical College of Wisconsin) Senior Research Scientist – Flow Cytometry (MD Anderson Cancer Center) Research Scientist – Hematological Malignancies (MD Anderson Cancer Center) Research Fellow – Stem Cell Biology & Engineering (New York Blood Center) Postdoctoral Fellow – Blood Development & Disease (University of Washington) Senior Research Assistant – Stem Cell Transplantation (MD Anderson Cancer Center) Postdoctoral Associate – Hematopoiesis and Leukemia (The Jackson Laboratory) Postdoctoral Fellowship – Translational Leukemia (Lund University) Postdoctoral Fellow – Myelodysplasia and Acute Myeloid Leukemia (UNSW) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|